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Introduction
Limb girdle muscular dystrophies (LGMD) are a clinically and genetically highly variable group of disorders (1, 2) (3, 6) , congenital myopathies (7, 8) , adult onset
LGMD (9) , and EDMD-like phenotype without cardiac involvement (10) . The full spectrum of titin phenotypes is yet to be defined as reports of patients with atypical presentations illustrate (6, 9, 11) .
Through the application of whole exome sequencing (WES) we have been able to identify recessive mutations in titin in four individuals with a muscle disorder, which was classified as LGMD but with notable similarities to EDMD. All four individuals share a common essential splice site mutation, which has also been reported in a heterozygous state in a patient with Dilated Cardiomyopathy (DCM). However, the heterozygote parent carriers in these families were healthy demonstrating the complexity of titinopathies in their genetic
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Materials and Methods

Patient selection
Five affected individuals from three families with genetically undiagnosed limb girdle muscular dystrophy were clinically assessed within the Newcastle University John Walton Muscular Dystrophy Research Centre, and had already undergone extensive diagnostic investigations. Informed consent for research was obtained for all patients under the protocol for Newcastle MRC Centre Biobank for Neuromuscular Diseases (REC reference:
08/H0906/28+5). Clinical data was extracted from medical records.
Genetic analysis
Exome sequencing was performed at the Broad Institute (Boston, USA), with Agilent SureSelect Human All Exon v2.0 (44Mb) on Illumina HiSeqXs platform (Illumina, Inc. San Diego, CA), and sequence alignment, variant calling and functional annotation was performed with Burrows Wheel Aligner, Genome Analysis Tool Kit and Variant Effect Predictor (VEP).
Variants were filtered using The Broad Institute's proprietary software, XBrowse (https://atgu.mgh.harvard.edu/xbrowse) to include only those that were rare (with a variant frequency of <0.01 in reference datasets (in house control dataset at The Broad Institute, 1000 Genomes, and ExAC)), which were predicted to be moderately to severely damaging by VEP and which passed the XBrowse quality filter. Identified variants from a list of known muscle disease genes (supplemental table 1) were reviewed manually. Given the high frequency of missense variants in TTN which are not of clinical significance we adopted a conservative approach and disregarded missense variants unless in a region where proven mutations had been previously reported. All truncating TTN variants (nonsense, frameshift, or essential splice site) mutations were confirmed by Sanger sequencing in the Northern Genetics Laboratory and segregated amongst available family members.
Muscle MRI and CT
Muscle MRI of lower limbs was performed in patients F1-II-1 and F2-II-2 and T1 weighted axial images were reviewed. Patient II-1 from family 3 was unable to undergo MRI due to having a PPM in situ and therefore CT of lower limbs was performed instead.
cDNA analysis
Total RNA from patient F1-II-1 biopsy was extracted with RNeasy Fibrous Tissue Mini kit 
Muscle biopsy immunoanalysis
Muscle biopsy immunoanalysis was performed by the Muscle Immunoanalysis Unit, Newcastle UK, using a standard panel of dystrophy antibodies as part of routine investigations (12) .
Muscle tissue from patient F1-II-1 underwent Western blot analysis of C-terminal titin fragments. Biopsies from a control individual free of muscular disease, FINmaj heterozygous TMD patient, and FINmaj homozygous LGMD2J patient served as controls. Frozen muscle biopsies were mechanically homogenized in Laemmli sample buffer. SDS-PAGE and western blotting were performed using standard protocols, and ECL-detection. Two different antibodies recognizing the last Ig domain M10 of titin were used for detection of titin Cterminal fragments, the polyclonal M10-1 (13) and the monoclonal 11-4-3 (6). Myosin heavy chain (MyHC) band was used as a loading control.
Results
Genetic results
In F1-II-1 WES data analysis identified four known muscle disease genes with rare variants that were predicted to be moderately to severely damaging (supplemental table 2). Single heterozygous variants in LAMA2, MSTN and SYNE1 were deemed unlikely to be pathogenic based on further examination of genetic data and correlation with phenotype in this patient. There were six rare variants in TTN, of which four were missense variants and two were predicted to be highly damaging by VEP: a nucleotide substitution in intron 362 In patient F3-II-1 WES data identified six known muscle disease genes with rare variants.
Review of these variants and comparison to the observed phenotype enabled variants in SIL1, SYNE2, PLEC, and ETFB to be discounted (supplemental table 2). There were six variants in TTN: three missense changes and two other variants predicted to be highly damaging. The first of these was the same essential splice site variant (c.107377+1G>A) also identified in families1 and 2; and the second was a novel nonsense variant in exon 329
Compound heterozygous variants in TTN that are predicted to be highly damaging to protein function were identified in all four patients. The common c.107377+1G>A splice site mutation identified in all three families has been observed in a heterozygous state in only two people out of >12,000 alleles in the Exac database (allele frequency: 0.00001661; one European (non-Finnish) individual and one African individual), consistent with this being a rare recessive disease causing allele. Construction of alleles in families 1 and 2 demonstrated evidence of a shared haplotype (figure 1) suggesting that variant has a shared origin in these families. This variant has recently identified in a heterozygous state in an individual with dilated cardiomyopathy (14). All identified truncating variants are expressed in both the N2-A and N2-B isoforms, which are the predominant isoforms in skeletal and cardiac muscle respectively. All variants were confirmed by Sanger sequencing and segregation of these variants within all available family members was consistent with pathogenicity (figure 1).
Clinical results
Clinical findings for all patients are summarised in table 1. 
Muscle imaging results
Muscle MRI in patient F1-II-1 at 17 years old did not demonstrate any evidence of muscle pathology (figure 3). Muscle MRI in patient F2-II-2 at age 28 years old demonstrated atrophy and diffuse fatty replacement in all muscle groups. The most severely affected muscles, the obturatorius and rectus femoris, showed some asymmetry. In the lower legs the peroneus longus, soleus and tibialis anterior muscles were more affected distally. CT of the lower limbs performed in patient F3-II-1 at age 48 years demonstrated in the thigh muscles that the semitendinosus was most affected with relative sparing of the medial vastus. In the distal lower limbs there was severe fatty replacement in calf muscles and asymmetric fatty replacement of muscle tissue in the tibialis anterior muscle in the left but not the right leg.
Muscle biopsy results
The muscle biopsy in patient F1-II-1 showed mild myopathic changes. Most fibres showed internal nuclei that tended to be located in a central position. NADH staining showed some central speckled areas of increased staining (supplemental figure 1) . All proteins analysed showed normal expression with the exception of calpain-3, which was undetectable on immunoblot (figure 4).
In patient F2-II-2 muscle biopsy at age 11 years old was dystrophic. A small sample was available for limited immunoanalysis but no specific abnormalities were identified on immunohistochemistry. Immunoblotting showed a reduction in calpain-3 using two different antibodies, with only very faint bands at 94kDa and lower molecular weight bands not visible (not shown).
In patient F3-II-1 the muscle biopsy showed dystrophic changes with significant fibre size variation and multiple internally placed nuclei. Immunohistochemistry showed some nonspecific cytoplasmic accumulation of myofibrillar proteins such as desmin and myotilin (figure 4). NADH staining did not show any pathological abnormality (supplemental figure 1).
Z line streaming was seen on electron microscopy (not shown). There was insufficient tissue for Western blotting to assess calpain-3.
cDNA analysis results
cDNA analysis of patient F1-II-1 muscle biopsy was performed in order to find out the effects of the mutations at mRNA level. The mutation in TTN exon 352 (c.97863G>A p.(Trp32621*)) creates a premature termination codon, which is believed to cause nonsense-mediated decay (NMD). This is suggested by the lower peak of the mutated G>A allele as seen on the cDNA sequencing graph (figure 5A). A smaller amount of transcript escaping from NMD can be seen. However cDNA sequencing is not a quantitative proof of NMD. The mutation in intron 362 (c.107377+1G>A) results in three different transcripts (figure 5B): 1) normal; 2) TTN missing the last 7 nt of Mex4 mRNA, causing frameshift and premature termination codon; again some residual expression of this truncated product is observed; 3) TTN missing the last 69 nt of Mex4 mRNA, causing an in-frame deletion, and replacement of 24 amino acids by an alanine residue.
Western blotting results
In order to confirm pathogenicity of the shared essential splice site mutation at the protein level, Western blot analysis of C-terminal fragments of titin was performed on muscle tissue from patient F1-II-1. This demonstrated a loss of small (< 20 kD) C-terminal fragments, and reduction of higher molecular weight M10 domain -containing bands (figure 6), consistent with truncation of the protein on both alleles as predicted by the genetic findings and cDNA analysis. The C-terminal titin fragment resulting from the transcript lacking the last 69 nt of Mex4 was not observed, probably due to its low abundance.
Discussion
Classification of TTN variants identified by WES is problematic due to the large number of variants in this gene as a consequence of its size, and the prevalence of heterozygous truncating variants in up to 2% of the normal population (14-16). We adopted a pragmatic approach, requiring two truncating variants per patient in order to consider them as putatively pathogenic. We describe four new individuals from three families with muscular dystrophy and contractures in association with compound heterozygous truncating mutations in TTN. All four individuals shared a common essential splice site mutation in the M-band of TTN, and in addition had a second truncating mutation (frameshift or nonsense in the A-band). Segregation amongst family members, correlation with muscle biopsy pathology, and Western blot for C-terminal titin fragments and calpain-3 are all in keeping with pathogenicity of the identified variants.
All four patients showed a common phenotype, namely onset in childhood or young adulthood of proximal muscle weakness, joint contractures and significantly elevated CK.
There were several similarities between our patients and those previously reported with skeletal myopathies due to recessive TTN mutations. The biopsy findings in patient F1-II-1 demonstrated multiple internalized and central nuclei, similar to that observed in patients described as centronuclear titin myopathy (8) .The absence of calpain-3 on WB has been documented in association with C-terminal titin mutations as well (10, 17) , due to the loss of calpain-3 binding site in the titin C-terminus. Since calpain-3 has no expression in heart muscle, this is not the cause of cardiomyopathy, but rather the loss of C-terminus itself or other ligands. The presence of prominent contractures in our patients and others has led to some patients with titinopathies being compared to EDMD (10) , and a limb girdle pattern of weakness classified as LGMD2J is well documented (17) . The pattern of muscle involvement observed on muscle MRI in patient F3-II-1 showed some features also reported in other titinopathies.
Notably, cardiac complications were observed in two of four patients reported here. Patient F1-II-1 developed cardiomyopathy in childhood and patient F3-II-1 had a history of atrial fibrillation requiring permanent pacemaker insertion. This was unsurprising given the central importance of titin in both cardiac and skeletal muscle tissue (18) and the fact that the identified mutations were present in both the predominant cardiac and skeletal muscle isoforms. Heterozygous truncating TTN variants have been reported to cause DCM (16) and co-existence of DCM and skeletal muscle disease in individuals with two truncating TTN variants is well known (7, 19) . Interestingly the essential splice site mutation (c.107377+1G>A) shared by all four patients has been reported by Roberts et al (2015) in association with isolated dilated cardiomyopathy (14). Our findings, with no clinically overt cardiac phenotype known in the heterozygous parents with this mutation, some of them already at advanced age, suggest that this variant demonstrates incomplete penetrance. LGMD2J where there is complete loss. 
